Brief: Tenaya Therapeutics Q3 Net Income USD -25.634 Million Vs. IBES Estimate USD -31.1 Million
06/11/2024 21:05
Nov 06 (Reuters) - Tenaya Therapeutics Q3 operating expenses USD 26.711 million. * Q3 pretax profit USD -25.634 million vs. IBES estimate USD -31.1 million * Q3 operating income USD -26.711 million vs. IBES estimate USD -31.7 million * Q3 basic EPS USD -0.3
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027